ClinicalTrials.gg
RecruitingNCT07849010Updated Oct 9, 2026

Disposable Noninvasive Skin Closure for Promoting Postoperative Wound Healing and Preventing Surgical Skin Scarring

An interventional study of Disposable Noninvasive Skin Closure Device (Shanghai Zhizhong Medical Technology Co., Ltd. Catalog No.: 240430PFF) in Scar, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 9, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Cicatrix with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Cicatrix · China.

Planned enrollment
29th of 34
25 · median 50
Started
2026
with 3 others
No phase
23 of 42
6 open now
Registered
40th of 42
by date

Among the 42 studies in Cicatrix with a site in China, this one is the 29th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, and was the 40th registered.

Cicatrix

613 studies on the registry are indexed under Cicatrix; 115 are open to participants now.

Browse Cicatrix studies →

Open to participants now

9 of the 42 studies in Cicatrix with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Cicatrix with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a disposable noninvasive skin closure device in promoting postoperative wound healing and reducing surgical scar formation. Participants will receive the device on one half of the surgical incision, with the other half serving as a control. Wound healing and scar appearance will be assessed during follow-up visits after surgery.

Read the detailed description

Surgical wounds can heal with visible scars. Tension on the skin may affect wound healing and scar formation. This study will evaluate whether a disposable noninvasive skin closure device can improve healing and reduce scar formation after plastic surgery.

Adults undergoing plastic surgery with an incision longer than 2 cm on the cheek, neck, trunk, or limbs will be enrolled. Each participant's incision will be divided into two parts. By random assignment, the device will be applied to one part of the incision, while the other part will receive standard postoperative care without the device. This within-participant comparison allows each participant to serve as their own control.

Participants will return for assessments at 1, 3, and 6 months after surgery. Blinded plastic surgeons will assess wound healing and scar appearance using standardized scar-rating tools. The study will evaluate whether the device is safe and effective for supporting postoperative wound healing and preventing surgical scar formation.

03

Conditions studied

  • Scar

Browse trials for

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 to 50 years undergoing plastic surgery
  • Surgical incision located on the cheek, neck, trunk, or limbs, excluding the hands and feet
  • Surgical incision longer than 2 cm
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • History of abnormal scar formation or keloids
  • disease
  • Surgical wound infection
  • Use of any scar treatment or wound treatment other than the study device during the study period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Tension Reduction

    The disposable noninvasive skin closure device will be applied to the randomly assigned half of the surgical incision for 3 months after surgery.

    Device: Disposable Noninvasive Skin Closure Device (Shanghai Zhizhong Medical Technology Co., Ltd. Catalog No.: 240430PFF)

  • No intervention
    Control

    The other half of the same surgical incision will receive routine postoperative care without the disposable noninvasive skin closure device.

Interventions

  • DeviceDisposable Noninvasive Skin Closure Device (Shanghai Zhizhong Medical Technology Co., Ltd. Catalog No.: 240430PFF)

    A disposable noninvasive skin closure device will be applied to the randomly assigned half of each participant's surgical incision after routine suturing. The device is designed to reduce tension across the skin surface without penetrating the skin. It will be used continuously for 3 months after surgery, while the other half of the incision will receive routine postoperative care without tension-reduction treatment.

06

What researchers measure

Primary outcomes

  1. Vancouver Scar Scale (VSS) score

    Blinded plastic surgeons will assess each half of the surgical incision using the VSS. Lower scores indicate a better scar outcome.

    Time frame: 6 months after surgery

Secondary outcomes

  1. Modified Patient and Observer Scar Assessment Scale (mPOSAS) score

    Blinded plastic surgeons will assess scar appearance for each half of the surgical incision using the mPOSAS. Lower scores indicate a better scar outcome.

    Time frame: 1, 3, and 6 months after surgery

  2. Device-related adverse events

    Skin redness, itching, and other adverse events related to use of the disposable noninvasive skin closure device will be recorded.

    Time frame: 1, 3, and 6 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Menkowitz B, Olivieri G, Belson O. Patient Satisfaction and Cosmetic Outcome in a Randomized, Prospective Study of Total Knee Arthroplasty Skin Closure Comparing Zip Surgical Skin Closure with Staples. Cureus. 2020 Jan 19;12(1):e6705. doi: 10.7759/cureus.6705. PubMed 32117656 ↗
  • Gorsulowsky DC, Talmor G. A novel noninvasive wound closure device as the final layer in skin closure. Dermatol Surg. 2015 Aug;41(8):987-9. doi: 10.1097/DSS.0000000000000399. No abstract available. PubMed 26218731 ↗
  • Tanaka Y, Miyamoto T, Naito Y, Yoshitake S, Sasahara A, Miyaji K. Randomized Study of a New Noninvasive Skin Closure Device for Use After Congenital Heart Operations. Ann Thorac Surg. 2016 Oct;102(4):1368-74. doi: 10.1016/j.athoracsur.2016.03.072. Epub 2016 Jun 1. PubMed 27261084 ↗
  • Kjonniksen I, Winderen M, Bruland O, Fodstad O. Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res. 1994 Apr 1;54(7):1715-9. PubMed 8137286 ↗
  • Gold MH, McGuire M, Mustoe TA, Pusic A, Sachdev M, Waibel J, Murcia C; International Advisory Panel on Scar Management. Updated international clinical recommendations on scar management: part 2--algorithms for scar prevention and treatment. Dermatol Surg. 2014 Aug;40(8):825-31. doi: 10.1111/dsu.0000000000000050. PubMed 25068544 ↗
  • Gold MH, Berman B, Clementoni MT, Gauglitz GG, Nahai F, Murcia C. Updated international clinical recommendations on scar management: part 1--evaluating the evidence. Dermatol Surg. 2014 Aug;40(8):817-24. doi: 10.1111/dsu.0000000000000049. PubMed 25068543 ↗

Individual participant data

Plan to share: No — IPD will not be shared because the study involves identifiable clinical photographs and sensitive personal health information. To protect participant privacy and confidentiality, individual participant data will remain restricted to the study team.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.

Of 174 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 8 months is below that.

Counting every sponsor, half of 207 studies reached it within 18 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 30, 2026
StartActual
Oct 8, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Oct 8, 2026 (actual)
Oct 9, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 9, 2026
    Start date Oct 1, 2026→Oct 8, 2026 (now actual)
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849010
Responsible party
SunYimou (Associate Chief Physician, Peking University Third Hospital) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 8, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Yimou Sun, M.D.
Contact
sym316@126.com
+86 13811625471
Mengying Jin, M.D.
Contact
1510301328@pku.edu.cn
+86 18811331677
Yimou Sun, M.D.
principal investigator · Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion